Moderna (MRNA) Receivables - Net (2017 - 2026)

Moderna (MRNA) has 10 years of Receivables - Net data on file, last reported at $203.0 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $203.0 million, down 18.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $203.0 million (down 18.47% YoY), and the FY2025 annual result was $368.0 million, down 47.28% from the prior year.
• Receivables - Net slipped to $203.0 million in Q1 2026 per MRNA's latest filing, from $368.0 million in the prior quarter.
• Over five years, Receivables - Net peaked at $3.2 billion in Q1 2022 and troughed at $137.0 million in Q1 2024.
• A 5-year average of $1.2 billion and a median of $1.1 billion in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net slumped 91.38% in 2023, then jumped 81.75% in 2025.
• A 5-year view of Receivables - Net shows it stood at $1.4 billion in 2022, then climbed by 14.37% to $1.6 billion in 2023, then sank by 55.93% to $698.0 million in 2024, then slumped by 47.28% to $368.0 million in 2025, then plunged by 44.84% to $203.0 million in 2026.
• Business Quant data shows MRNA's Receivables - Net at $203.0 million in Q1 2026, $368.0 million in Q4 2025, and $2.0 billion in Q3 2025.